Loading clinical trials...

Accuracy of Spircare Device as Compared to the Conventional Plethysmograph | Clinical Trials | Clareo Health

UNKNOWN

Accuracy of Spircare Device as Compared to the Conventional Plethysmograph

NCT03056066•Spircare Ltd.

Summary

The purpose of this study is to assess the accuracy of FRC and airway resistance calculate values of Spircare device as compared to the conventional body plethysmograph in healthy adults and patients with obstructive and restrictive pulmonary diseases/disorders.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Signed Informed consent.
•2. Age≥18 year.
•3. Subject is cooperative and capable of following instructions.
•4. Phase I: Healthy asymptomatic subjects, never smokers without known history of respiratory, cardiovascular, hepatic, renal or metabolic disease.
•5. Phase II: Chronic pulmonary patients with lung volume disorders:
•* COPD
•* Asthma
•* Restrictive diseases such as pulmonary fibrosis, other interstitial lung diseases, kyphoscoliosis, neuro-muscular disorders.

Exclusion Criteria

•1. Subjects unable or unwilling to give informed consent.
•2. Subjects who are unable to satisfactorily perform routine, full lung function testing (due to non-compliance or claustrophobia).
•3. History suggesting upper respiratory infection during the four weeks prior to testing
•4. Physical activity during 1 hour prior to the Study.
•5. Patients with a tracheostomy.
•6. Pregnant women.

Locations (1)

"Meir" Medical Center

Kfar Saba, Israel

Key Dates

Start Date

July 31, 2017

Primary Completion Date

November 1, 2018

Completion Date

January 1, 2019

Last Updated

May 1, 2018

Enrollment

ESTIMATED participants

Conditions

COPD AsthmaPulmonary Fibrosis

Interventions

Plethysmograph

DEVICE

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622

Idiopathic Pulmonary FibrosisProgressive Pulmonary Fibrosis

View study

RECRUITINGPHASE3

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

NCT07299695

Idiopathic Pulmonary FibrosisAcute Exacerbation of Idiopathic Pulmonary Fibrosis

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 1, 2018Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Accuracy of Spircare Device as Compared to the Conventional Plethysmograph

Inclusion Criteria

Exclusion Criteria

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

Intravenous Immunoglobulin for the Treatment of Acute Exacerbations of Idiopathic Pulmonary Fibrosis

Study on the Efficacy of Quercetin Intake in Patients With Fibrotic Interstitial Lung Diseases.

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males

Validation of the C-mo System - Cough Monitoring